Pegylated Interferon and Ribavirin Treatment for Hepatitis C Virus Infection
2010

Advancements in Hepatitis C Treatment

Sample size: 122 Editorial Evidence: moderate

Author Information

Author(s): Tatehiro Kagawa, Emmet B. Keeffe, Ming-Lung Yu

Conclusion

The treatment of chronic hepatitis C has significantly improved over the past 20 years, with sustained virologic response rates increasing from less than 10% to close to 75% with new therapies.

Supporting Evidence

  • The sustained virologic response (SVR) rate increased from 8%-9% with interferon monotherapy to 30% with ribavirin, and then to 40%-50% with peginterferon plus ribavirin.
  • Recent literature shows that achieving an SVR leads to slowed disease progression and improved health outcomes.
  • Adherence to peginterferon and ribavirin was the only predictor of SVR in a study of 122 patients.

Takeaway

Doctors have found better ways to treat hepatitis C, helping more people get better over the years.

Participant Demographics

Patients with chronic hepatitis C, including special populations like those undergoing chemotherapy and hemodialysis.

Digital Object Identifier (DOI)

10.1155/2010/275274

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication